The aim was to determine the values of p53 tumour expression and microsatellite instability (MSI) phenotype to predict benefit from adjuvant chemotherapy of colon cancer by 5-fluorouracil and leucovorin (FL) alone or with oxaliplatin (FOLFOX).
introduction
Colorectal cancer (CRC) is the second leading cause of death from cancer in Western countries. In the absence of treatment, almost half of the patients undergoing potentially curative surgery relapse or die of metastases. Postoperative adjuvant treatment with 5-fluorouracil (5-FU) plus levamisole given 1 year was shown to reduce the mortality among patients with stage III colon cancer [1] . Later, several clinical trials established 6 months of treatment with 5-FU plus leucovorin (FL) as the standard adjuvant chemotherapy for stage III colon cancer [2, 3] . The addition of oxaliplatin to this regimen (FOLFOX) was demonstrated to improve the adjuvant treatment of stage III colon cancer by reducing the risk of recurrence and increasing overall survival (OS) [4] . The results of the MOSAIC trial establishing the effectiveness of oxaliplatin and FL combination as adjuvant therapy for colon cancer have been recently confirmed and extended [5] . Nevertheless, the benefit from oxaliplatin is at the cost of an increased incidence of adverse effects, notably haematological toxicity and peripheral neuropathy [4, 5] .
Microsatellite instability (MSI) and p53 alterations are among the most frequent tumour alterations associated with colorectal oncogenesis. The MSI pathway resulting from a defect in mismatch repair (MMR) accounts for 15% colon cancers [6] . p53 gene alterations are found in half of all CRCs and are more frequent in tumours displaying chromosomal instability than in MSI tumours [7] [8] [9] [10] . Missense gene mutations occurring in tumour cells generally lead to the accumulation of p53 so that it becomes detectable by immunohistochemistry (IHC). Overall, there is a good correlation with concordance between the two techniques being at 70% [11, 12] .
Although several tumour characteristics including MSI and p53 status have been proposed to influence the clinical outcome of CRC, none has been validated for clinical use yet. Patients whose tumour displays MSI are generally regarded as having a better prognosis, but the impact of MSI on tumour response to 5-FU-based adjuvant chemotherapy remains largely controversial [8, [13] [14] [15] [16] [17] [18] [19] . Early reports indicated that 5-FU-based adjuvant chemotherapy improved survival of patients with MSI tumour, but recent studies have challenged this conclusion [13, [15] [16] [17] . Evidence indicating that 5-FU-based chemotherapy may even be detrimental to patients with MSI tumours has further been reported [16] . The prognosis significance of p53 alterations in patients treated by surgery alone remains unclear and controversial. Most studies reported that tumours harbouring p53 mutations [11, 20, 21] or overexpressing p53 [22] are of worse prognosis, but others failed to observe significant differences in OS [23] . Regarding the impact of p53 alterations on the survival benefit from 5-FU-based adjuvant chemotherapy of patients with CRC, there is a general agreement concluding that neither mutations nor overexpression of p53 influences the outcome of patients [9, 10, 22, 24, 25] .
To our knowledge, the impact of p53 status and MSI phenotype as markers to predict benefit from the adjuvant chemotherapy by FL with oxaliplatin has not been evaluated yet. In the present study, we defined p53 expression and MMR status of tumour samples by IHC in a series of patients with stage III colon cancer receiving FL or FOLFOX and analysed their relationship with disease-free survival (DFS).
patients and methods patients
This retrospective study included 233 consecutive patients who underwent curative surgical resection of histologically proven tumour-node-metastasis stage III colon cancer treated by FL with or without oxaliplatin and whose tumour could be retrieved from the tumour collection. Patients were operated from December 1997 to March 2006 at the Saint-Antoine Hospital (n = 161) or at the Institute Mutualiste Montsouris (n = 72) (Paris, France). For all patients, chemotherapy started at the Saint-Antoine Hospital within 7 weeks after surgery, where follow-up was further conducted. Patients received adjuvant chemotherapy during 6 months by either FL (n = 124) or FOLFOX (n = 109). Patients were non-randomly assigned FL or FOLFOX, except for the 39 patients who were part of the MOSAIC study, with 22 receiving FL and 17 FOLFOX. The choice of chemotherapeutic regimen for the remaining 194 patients depended on the date at which treatment started. Patients whose treatment started before June 2003 received FL (n = 97), while those treated after October 2003 were given FOLFOX (n = 84); patients whose treatment began from June to October 2003 were given either FL (five patients) or FOLFOX (eight patients). The procedures followed in this study were in accordance with the ethical standards of the Saint-Antoine Hospital Institutional Ethics Committee.
treatment and follow-up
In the group receiving FL, 37 patients were treated by the LV5FU2 standard regimen and 87 by the LV5FU2 simplified regimen [3, 26] . The FOLFOX The follow-up protocol consisted in physical examination with biological tests and measurement of the carcinoembryonic antigen level, pulmonary Xray and abdominal ultrasonography carried out alternately with computed tomography (CT) every 3 months during the first 3 years after surgery; during the next 2 years, CT was carried out every 6 months, then annually. Evaluations were conducted independently of the type of chemotherapy and did not vary with time. Patient follow-up was defined as the time between surgery and the last hospital contact (scheduled follow-up or telephone contact) or disease recurrence. At the end of follow-up, 19 (17%) patients in the group given FOLFOX had relapsed, as compared with 40 (32%) in the FL group. The mean follow-up was 42 and 52 months for the FOLFOX and FL groups, respectively (median 40 and 52 months, respectively).
histopathologic evaluation and tissue microarray technique
Cases of colon adenocarcinomas were retrieved retrospectively from the files of the departments of pathology. Tumour type and grade of differentiation were determined according to the World Health Organization criteria. One block of formalin-fixed paraffin-embedded adenocarcinoma tissue comprising an area of normal colonic mucosa adjacent to the tumour was selected in each case. Haematoxylin and eosin whole sections of each donor block were used to select non-necrotic areas rich in tumour glands. Three core biopsies of 0.6 mm in diameter were punched from the donor blocks and positioned in a recipient paraffin array block, using a tissue microarrayer (Beecher Instruments, Woodland, MD), as described [27] . The array blocks were cut at room temperature with a standard microtome (Microm, Heidelberg, Germany).
immunohistochemistry
Sections of 4 lm from the tissue microarray blocks were processed as previously described [27] . Mouse mAbs to p53 (clone DO-7; Dako Glostrup, Denmark), MLH1 (clone G168-728; Pharmingen, San Diego, CA), MSH2 (clone FE11; Calbiochem, Cambridge, MA) and MSH6 (clone 44; Becton Dickinson, Lexington, NC) were used [27] . The DO-7 antibody was chosen to label p53 based on previous studies showing that this antibody was the most sensitive and specific, with p53 expression being strongly associated with p53 mutation in CRC [11, 28, 29] . Tumours were classified as p53 positive (p53 pos ) when >50% of nuclei in carcinomatous epithelium were immunostained, as previously described [27, 29, 30] . The MSI phenotype was defined as the complete lack of MLH1, MSH2 or MSH6 expression by IHC, a technique that is strongly correlated with the molecular MSI testing. Tumours were considered negative when there was a complete absence of nuclear staining of neoplastic cells in the presence of an internal positive control [27] . Whole sections of donor blocks and tissue array sections were read separately by two pathologists who were not aware of the patients' clinical characteristics; nine discordant cases were reviewed to reach a consensus. In both models, stepwise selection procedure was carried out to obtain the presented models; the selections were based on adjusted P values (Table 5) . Besides, a goodness-of-fit test was carried out for each fitted Cox regression model to verify the appropriateness of the proportional hazards assumption [31] .
results

patient characteristics
The clinicopathological characteristics of the patients are summarised in Table 1 . LNR was preferred to N or T stages based on recent publications showing that LNR is the most significant prognostic factor for both OS and DFS in patients with at least 10 LN removed, which was the case for all patients but six, in whom nine LN were recovered [32, 33] . In addition, the median LNR was further identified as an adequate breakpoint for predicting DFS of stage III patients [33] . Thus, we stratified patients as either £0.09 (low) or >0.09 (high). Among the 232 tumours whose p53 status could be defined, 123 (53%) were classified as p53 pos ; the only significant differences observed between p53-negative (p53 neg ) and p53 pos tumours are the tumour stage and location, with the latter being more often distal, as already reported [7, 11, 25] . Of the 233 colon adenocarcinomas examined, 201 (86%) displayed normal nuclear expression of MLH1, MSH2 and MSH6 proteins and were assigned as microsatellite-stable (MSS) tumours. Among the remaining tumours, 22 showed loss of MLH1 expression including one case with loss of both MLH1 and MSH6 expression, seven demonstrated loss of MSH2 expression and three showed selective loss of MSH6 expression. The 32 (14%) (Table 3) . One exception was observed in the group of p53 pos tumours, in which the proportion of proximal tumours was higher among patients treated with FL than among those treated with FOLFOX (29 of 61 versus 13 of 48; P = 0.05). Another difference was seen in the group of patients with MSI tumours in whom the proportion of patients with high LNR, corresponding to those with worse prognosis, was lower in the group treated by FL than in the group receiving FOLFOX (P = 0.04).
relationship between p53 expression, MSI status and DFS
The 3-year DFS of patients treated by FOLFOX and FL regimen was 82% and 71%, respectively (HR 0.55; 95% CI 0.33-0.92; P = 0.02) (data not shown), confirming that adding oxaliplatin to a regimen of FL improves the adjuvant treatment of colon cancer [4, 5] . By contrast, patients with p53 neg tumours did not benefit from the addition of oxaliplatin to FL regimen; the 3-year DFS was 78% in the group given FOLFOX compared with 73% in the FL group (HR 0.82; P = 0.60) ( Figure 1A ), whereas patients with p53
pos tumours who received FOLFOX did show a significantly better 3-year DFS compared with those who received FL alone: 86% versus 70% (P = 0.01) ( Figure 1B ). In the subset of patients with MSS tumours, adding oxaliplatin to a regimen of FL remained beneficial, but the improvement was slight and was not statistically significant; the 3-year DFS was 80% in the group given FOLFOX and 74% in the FL group (P = 0.15) ( Figure 1C) . As for the patients with MSI tumours, the addition of oxaliplatin to FL regimen improved significantly the 3-year DFS; 3-year DFS was 100% versus 58% in the FOLFOX and FL groups, respectively (P = 0.01) ( Figure 1D) . No recurrence has been diagnosed so far in the group of patients with MSI tumours given FOLFOX, whose follow-up varied from 27 to 98 months, with a median of 41 months. The same conclusions could be drawn when the analysis of p53 expression was restricted to the group of 201 patients with MSS tumours (data not shown). Again, the addition of oxaliplatin to FL significantly improved DFS of patients with MSS-p53 pos tumours (3-year DFS 85% versus 71%; HR 0.41, 95% CI 0.16-0.89; P = 0.02) but not of those with MSS-p53 neg tumours (3-year DFS 73% versus 77%; HR 1.17, 95% CI 0.52-2.66; P = 0.70).
univariate and multivariate analyses of DFS
In univariate analyses of DFS, LNR was the most significant prognostic factor with a HR of 2.3 for patients with high LNR, Figure 1 . Kaplan-Meier estimates of disease-free survival (DFS) in the groups of patients given 5-fluorouracil and leucovorin (FL) or FOLFOX according to tumour p53 expression and microsatellite instability (MSI) phenotype. Univariate analyses of uncensored DFS were carried out according to the method of Kaplan and Meier. For statistical analyses, the follow-up data were not censored, but only the first 8 years are shown, as there were no events later on. The percentages of patients who had not recurred at 36 months are indicated on the curves. The hazard ratios and 95% confidence intervals for recurrence were compared using a two-sided log-rank test.
original article Annals of Oncology compared with those with low LNR (P = 0.002) ( Table 4) . A statistically significant better DFS was also seen for patients given FOLFOX (P = 0.02) ( Table 4) .
Cox proportional hazards models were used for multivariate analyses. In model 1, all variables were included irrespective of their statistical significance in the univariate analysis. The results obtained in this model were essentially unchanged compared with the results obtained by carrying out univariate analysis (Table 5 ). Yet, LNR remained in the model as an independent prognostic factor (P < 0.002), as well as the effects of chemotherapy regimen (P = 0.02) ( Table 5 ). Model 2 was specifically designed to test whether there was an interaction between chemotherapy and p53 expression and consisted in adding interactive terms to the covariates tested in model 1, FL and p53 neg tumours being considered as the references. Using a goodness-of-fit test, we first verified that the null hypothesis, i.e. that the hazards were proportional, was accepted in both multivariate analysis models; as expected, P values were >0.05 (0.24 and 0.13 for models 1 and 2, respectively). In model 2, high LNR remained a strong prognosis factor associated with shorter DFS. Moreover, the DFS difference observed between FOLFOX and FL treatments was significant only for the p53 pos tumours (P = 0.03), but not for the p53 neg tumours (P = 0.26), indicating that there was a strong interaction between chemotherapeutic regimen and p53 expression status. Based on this result, we further investigated the prognosis factors in the subgroups of patients based on p53 expression using Cox proportional hazards model 1. LNR and chemotherapy were equally strong prognosis factors (P = 0.02) for the patients with p53 pos tumours, whereas LNR was the only prognosis factor for those with p53 neg tumours (P = 0.04) ( Table 5) .
discussion
To our knowledge, this study is the first that evaluates the impact of p53 status and MSI phenotype on DFS of patients with stage III colon cancer treated by FL alone or with oxaliplatin. These genetic alterations play a crucial role in colorectal carcinogenesis, occurring at fairly high frequencies and are both involved in DNA damage signalling and repair of platinum-based chemotherapeutic agents. The DFS after 3 years of median follow-up was analysed as it has been reported to be an appropriate end point for adjuvant colon cancer clinical trials, being highly correlated with OS, reflecting the efficacy of adjuvant treatment [34] . When analysing the overall population, we confirmed that patients receiving oxaliplatin appeared to experience a longer DFS compared with the patients given FL alone; the HR for recurrence (0.55) was lower in our series than in the MOSAIC (0.77) or National Surgical Adjuvant Breast and Bowel Project C-07 (0.80) trials [4, 5] . The lower HR may reflect the fact that only stage III patients were included in the present study, while the previous trials also included stage II patients who benefited from the addition of oxaliplatin to a lesser extent [4, 5] . As this was not a randomised study, other factors may have further contributed to the better efficacy of FOLFOX. In particular, a number of characteristics that had previously been reported to influence prognosis for patients with colon cancer, such as the performance status, the ethnical origin or the body mass index, have not been investigated in our study. Similarly, as surgery has a major impact on the treatment of colon cancer at early stages, improved surgical techniques might have contributed to the longer DFS of patients given FOLFOX, as most of them were diagnosed more recently.
In this retrospective study, we further evaluated the efficacy of treatment by FL alone or with oxaliplatin in patient subsets. Regarding patients whose tumour lacked detectable p53 expression, there were no significant differences in DFS or rate of recurrences upon addition of oxaliplatin to FL regimen. Yet, adding oxaliplatin to FL regimen significantly improved DFS of patients provided that their tumour overexpressed p53. Carrying out a statistical test for interaction between p53 and chemotherapy further indicated that the patients whose tumour expressed detectable p53 predominantly contributed the differences in DFS rates according to therapy observed when analysing the overall population. The only group of patients having a reduced risk of recurrence consisted of patients whose tumour expressed p53 and who were treated with FOLFOX.
Interestingly, although the number of patients with MSI tumours was rather low, the DFS rate among those who were treated with FOLFOX was significantly higher than when treated with FL regimen, even though the LNR was lower in the latter group of patients, a parameter considered of better prognosis [32, 33] . Indeed, no recurrence was observed among patients with MSI tumours treated with FOLFOX, hampering multivariate analysis to test whether MSI was an independent factor. The fact that patients with MSI tumours treated with FL had the lowest DFS rate after 3 years of follow-up is noteworthy in view of the better prognosis of MSI tumours. This observation is reminiscent of several studies showing that 5-FU-based adjuvant chemotherapy does not benefit patients with MSI colon cancer and may even lead to worse outcomes [16, 17] . Whether FL regimen is deleterious for patients with MSI tumours will be difficult to establish in the future since withholding chemotherapy in clinical trials for stage III colon cancer is somewhat unethical. Altogether, if verified in future studies, these observations indicate that patients with MSI tumours should be given FOLFOX rather than FL regimen, if treated. Since oxaliplatin-based regimens are currently used in the treatment of patients with metastatic colon cancer, whether MSI or p53 expression influences clinical outcome should be established. The predictive and prognostic value of MSI was recently investigated in two series of patients with advanced CRC treated with 5-FU/oxaliplatin-based chemotherapy [35, 36] . Although both studies failed to demonstrate a relationship between the MSI status and the survival of patients, this finding must be interpreted taking into account the very low number of MSI cases. To the best of our knowledge, the impact of p53 on the clinical outcome of patients with metastatic colon cancer treated with FOLFOX has not been reported yet.
Numerous studies have investigated the molecular mechanisms involved in the response to chemotherapeutic drugs, with the aim of identifying novel predictive markers of sensitivity or resistance to these agents. In particular, loss of MMR activity was shown to confer resistance to cisplatin, but without affecting the response to oxaliplatin [37, 38] . DNA adducts induced by cisplatin are recognised by the MSH2-MSH6 MMR complex, a process that ultimately drives cells into apoptosis [37] . By contrast, oxaliplatin-induced adducts are not recognised by MSH2-MSH6 but may be removed from DNA by the nucleotide excision repair system or by recombinational repair, two repair pathways involving genes that may be targeted by MSI-driven mutations [39, 40] . Thus, hypersensitivity of MSI tumours to oxaliplatin may reflect the fact that recombination and nucleotide excision repair pathways are frequently affected in MSI CRC [39] . The role of p53 in the cellular response to oxaliplatin has also been investigated using various in vitro models [41] [42] [43] . Altogether, these studies showed that human CRC cell lines lacking functional p53 were generally more resistant to 5-FU and oxaliplatin than the p53 wild-type cell lines analysed and that 5-FU and oxaliplatin sensitisation to Fas-mediated apoptosis required wild-type p53 [41] [42] [43] . The rational for the apparent discrepancy between our observations and the results obtained in vitro using various cell lines remains unclear. Of note, however, is the fact that most CRC cell lines with wild-type p53 used in the aforementioned studies also display MSI. Thus, additional experiments are required to clarify the respective roles of p53 and MSI in tumour sensitivity to oxaliplatin.
In conclusion, this is the first study showing that both p53 expression and MSI phenotype may have an impact on the efficacy of adjuvant treatment by FOLFOX in patients with stage III colon cancer. As this study was not randomised and included a limited number of patients, our observations need rather be considered as promoting new hypotheses than drawing definitive conclusions. The fact that the clinical original article Annals of Oncology outcome of patients whose tumour lacked detectable expression of p53 was not improved by adding oxaliplatin to FL regimen constitutes a major outcome of this study, which should now be validated in larger independent and randomised series in order to translate into clinical practice. Future trials comparing FOLFOX to FL in adjuvant treatment will probably never be done, impeding the possibility of a prospective validation. In view of this, the only step towards clinical application could be obtained by analysing materials of previously completed trials such as the MOSAIC study, a goal that is currently pursued. 
